A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division.
Pharmaceutical Division
Breast cancer is the most common and most fatal malignancy for women worldwide. Overall, 15 percent of women will be diagnosed with breast cancer during their lifetime. Although breast cancer may initially be hormone-dependent and treated with anti-estrogen therapy such as tamoxifen, metastatic breast cancer will recur in 50 percent of patients within 5 years of initial treatment. The survival rate of women receiving chemotherapy is 10 to 20 percent after 5 years.
The first FDA-approved biological therapy for metastatic breast cancer, Genentech's Herceptin, was launched very successfully in 1998. Herceptin, the first antibody-based cancer therapy, is a humanized monoclonal antibody that represses erbB2. It is used as a therapeutic agent to treat patients with metastatic breast cancer over-expressing erbB2, which constitutes only 20 percent of all metastatic breast cancers. Currently, there is no similar clinical treatment for breast cancer patients not over-expressing erbB2.
Recently, A&G co-founder Dr. Ginette Serrero has cloned the novel growth factor PCDGF that is over-expressed in all metastatic breast cancers. It has been shown that inhibiting PCDGF expression or action leads to a 98 percent inhibition of human breast tumor formation in experimental animals. A&G has successfully obtained the exclusive patent rights to develop both diagnostic tools and therapeutic agents using monoclonal anti-PCDGF antibodies to address the market need for treating metastatic non-erbB2 breast cancers.
Monoclonal Antibody Services Division
A&G owns a proprietary technology that enables A&G to provide its customers the fastest monoclonal antibody production service in the industry (60 days versus an average of 180 days) and with the highest success rate (85 percent compared to an industry average of 25 percent). The Monoclonal Antibody Services Division is also developing monoclonal antibodies to key growth factors/receptors for licensing.
| Contact Details: |
| 600E Lombard St., Suite 511 |
| Baltimore |
| MD |
| 21202 |
| United States of America |
| Tel: | 410-230-0901 |
| Fax: | 410-230-0903 |
| Email: | agrx@agrx.net |
| WWW: | www.agrx.net/
|
|
Loading...
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 768 times since April 2007, the link to the organisation's website has been followed 122 times
Recent Search Terms used to find this page: A G Pharmaceutical | A G Pharmaceutical | A G PHarmaceutical | a g pharmaceuticals, md | was incorporated | .
Search for more companies in Baltimore
Search for more companies in MD
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
A&G Pharmaceutical Incorporated
